Analysis of the Efficacy, Progression-Free Survival, and Safety of Anlotinib in Advanced Lung Cancer Treatment

Abstract

Objective: To analyze the clinical efficacy, progression-free survival, and safety of anlotinib in the treatment of advanced lung cancer. Methods: A retrospective analysis was conducted using data from 60 patients with advanced lung cancer treated with anlotinib from May 2019 to May 2021. This analysis aimed to comprehensively evaluate the clinical efficacy, progression-free survival, and adverse reactions of anlotinib. Results: The median progression-free survival (PFS) for the 60 patients was 5.79 months, with an overall response rate (ORR) of 21% and a disease control rate (DCR) of 90%. In the first-line group, the median PFS was 6.20 months, ORR was 76.92%, and DCR was 84.61%. The second-line group showed a median PFS of 6.30 months, ORR of 28.57%, and DCR of 90.48%. In the third-line group, the median PFS was 5.34 months, ORR was 19.23%, and DCR was 92.30%. The single-agent group exhibited a median PFS of 5.09 months, ORR of 23.33%, and DCR of 76.67%. In the combination group, the median PFS was 6.53 months, ORR was 46.67%, and DCR was 100%. The combination group demonstrated a significantly higher medication effect than the single-drug group, and adverse drug reactions were mostly grade 1–2. Conclusion: Anlotinib exhibits a better disease control rate and survival benefit in the treatment of advanced lung cancer. The combination effect is superior to monotherapy, with relatively controllable adverse effects.